Cargando…

Prognostic Value of the Evolution of HER2-Low Expression after Neoadjuvant Chemotherapy

PURPOSE: Patients with human epidermal growth factor receptor 2 (HER2)–low advanced breast cancer can benefit from trastuzumab deruxtecan. Given the unclear prognostic characteristics of HER2-low breast cancer, we investigated the prognostic characteristics of HER2-low expression from primary tumor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Youzhao, Zhu, Mingda, Zhang, Jingyang, Lv, Minhao, Chen, Xiuchun, Liu, Zhenzhen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582545/ https://www.ncbi.nlm.nih.gov/pubmed/37024094 http://dx.doi.org/10.4143/crt.2022.1633

Ejemplares similares

Impact of residual disease biomarkers on the prognosis of HER2‐positive breast cancer following neoadjuvant therapy
por: Ma, Youzhao, et al.
Publicado: (2023)

Dyslipidemia is associated with a poor prognosis of breast cancer in patients receiving neoadjuvant chemotherapy
por: Ma, Youzhao, et al.
Publicado: (2023)

Lymphocyte-to-Monocyte Ratio is Associated with the Poor Prognosis of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
por: Ma, Youzhao, et al.
Publicado: (2021)

Evaluation of whether adjuvant chemotherapy can be safely omitted for older female patients with ER-positive, HER2-negative N1 breast cancer: a study based on the SEER database
por: Lv, Minhao, et al.
Publicado: (2021)

Exploration of prognostic factors and the value of adjuvant chemotherapy in T1a,bN0M0 triple-negative breast cancer: a prospective cohort study based on the SEER database
por: Wu, Junzhao, et al.
Publicado: (2022)

Association Between the HER2 Protein Expression Level and the Efficacy of Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
por: Yan, Hui, et al.
Publicado: (2020)

Neoadjuvant Efficacy of Three Targeted Therapy Strategies for HER2-Positive Breast Cancer Based on the Same Chemotherapy Regimen
por: Zhu, Jiujun, et al.
Publicado: (2022)

Prognostic Value of Lymph Node Ratio in Breast Cancer Patients with Adequate Pathologic Evidence After Neoadjuvant Chemotherapy
por: Ai, Xiang, et al.
Publicado: (2020)

The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
por: Wang, Wei, et al.
Publicado: (2022)

Predictive and Prognostic Value of TRIM58 Protein Expression in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy
por: Zheng, Yi-Zi, et al.
Publicado: (2022)

Neoadjuvant chemotherapy promotes the expression of HER3 in patients with ovarian cancer
por: Mizuno, Takaaki, et al.
Publicado: (2020)

Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy
por: Yang, Xia, et al.
Publicado: (2018)

Prognostic values of EDNRB in triple-negative breast cancer
por: Liu, Shaoqing, et al.
Publicado: (2020)

ELOVL2-AS1 inhibits migration of triple negative breast cancer
por: Zhu, Mingda, et al.
Publicado: (2022)

Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer
por: Zhou, Shuling, et al.
Publicado: (2022)

Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab
por: Cheng, Huan, et al.
Publicado: (2014)

Predictive and prognostic value of ZEB1 protein expression in breast cancer patients with neoadjuvant chemotherapy
por: Wu, Ziping, et al.
Publicado: (2019)

Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy
por: Robl, Bernhard, et al.
Publicado: (2015)

The Predictive Value of Serum HER2/neu for Response to Anthracycline-Based and Trastuzumab-Based Neoadjuvant Chemotherapy
por: Lee, Jung Sun, et al.
Publicado: (2012)

Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
por: Ilie, Silvia Mihaela, et al.
Publicado: (2023)

The Prognostic Value of BRCA1 mRNA Expression Levels Following Neoadjuvant Chemotherapy in Breast Cancer
por: Margeli, Mireia, et al.
Publicado: (2010)

Evaluation of predictive and prognostic value of androgen receptor expression in breast cancer subtypes treated with neoadjuvant chemotherapy
por: Shi, Zhendong, et al.
Publicado: (2023)

Marginal resection for osteosarcoma with effective neoadjuvant chemotherapy: long-term outcomes
por: Xu, Ming, et al.
Publicado: (2014)

Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy
por: Cao, Maria D, et al.
Publicado: (2012)

Development and validation of a prognostic model for HER2-low breast cancer to evaluate neoadjuvant therapy
por: Li, Xiaoping, et al.
Publicado: (2023)

Evolution and clinical significance of HER2-low status after neoadjuvant therapy for breast cancer
por: Shang, Jiuyan, et al.
Publicado: (2023)

Efficacy evaluation of neoadjuvant chemotherapy in patients with HER2-low expression breast cancer: A real-world retrospective study
por: Tang, Lingfeng, et al.
Publicado: (2022)

Clinical significance and prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients
por: He, Yang, et al.
Publicado: (2023)

Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer
por: Palmieri, Carlo, et al.
Publicado: (2015)

Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
por: Natoli, Clara, et al.
Publicado: (2013)

Stability and prognostic value of Slug, Sox9 and Sox10 expression in breast cancers treated with neoadjuvant chemotherapy
por: Riemenschnitter, Cosima, et al.
Publicado: (2013)

Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy
por: Exner, Ruth, et al.
Publicado: (2016)

Predictive and prognostic value of EPIC1 in patients with breast cancer receiving neoadjuvant chemotherapy
por: Xu, Yaqian, et al.
Publicado: (2020)

Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors
por: Buzatto, I.P.C., et al.
Publicado: (2017)

HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases
por: Cai, Mengyuan, et al.
Publicado: (2023)

The Prognostic Value of Lymph Node Ratio after Neoadjuvant Chemotherapy in Patients with Locally Advanced Gastric Adenocarcinoma
por: Zhu, Kankai, et al.
Publicado: (2021)

Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy
por: Arai, Roberto J., et al.
Publicado: (2018)

Prognostic value of XIAP and survivin expression in locally advanced breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy
por: Pluta, Piotr, et al.
Publicado: (2019)

Prognostic role of iodine values for gastric cancer after neoadjuvant chemotherapy: a strong independent prognostic factor
por: Zhang, Yang, et al.
Publicado: (2022)

Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer
por: Kurozumi, Sasagu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3c2q8bb4078gmoagjd7546uieh